Yi‐Hung Lin
About
Yi‐Hung Lin is a scholar working on Epidemiology, Hepatology and Molecular Biology.
According to data from OpenAlex, Yi‐Hung Lin has authored 52 papers receiving a total of 671 indexed citations (citations by other indexed papers that have themselves been cited), including 44 papers in Epidemiology, 41 papers in Hepatology and 2 papers in Molecular Biology. Recurrent topics in Yi‐Hung Lin's work include Liver Disease Diagnosis and Treatment (44 papers), Hepatitis C virus research (34 papers) and Hepatitis B Virus Studies (28 papers). Yi‐Hung Lin is often cited by papers focused on Liver Disease Diagnosis and Treatment (44 papers), Hepatitis C virus research (34 papers) and Hepatitis B Virus Studies (28 papers). Yi‐Hung Lin collaborates with scholars based in Taiwan, United States and Mongolia. Yi‐Hung Lin's co-authors include Chia‐Yen Dai, Ming‐Lung Yu, Wan‐Long Chuang, Yu‐Kang Tu, Wen-Chen Chung, Jee‐Fu Huang, Hsein‐Kun Lu, Po‐Cheng Liang, Chung‐Feng Huang and Ming‐Lun Yeh and has published in prestigious journals such as PLoS ONE, Scientific Reports and International Journal of Molecular Sciences.
In The Last Decade
Yi‐Hung Lin
49 papers receiving 654 citations
Peers
Yi‐Hung Lin
Alica Kubesch Germany
I Nakajima Japan
Yoo Sang Yoon South Korea
Gabriel Ionescu United States
Russell Wesson United States
Hellevi Ruokonen Finland
Charles Morrison Australia
M. de la Torre Spain
Antonio Ramos‐De la Medina Mexico
Rebecca J. Cannan New Zealand
Citations per year, relative to Yi‐Hung Lin Yi‐Hung Lin (= 1×)
peers
Alica Kubesch
Countries citing papers authored by Yi‐Hung Lin
Since
Specialization
Citations
This map shows the geographic impact of Yi‐Hung Lin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yi‐Hung Lin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yi‐Hung Lin more than expected).
Fields of papers citing papers by Yi‐Hung Lin
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Yi‐Hung Lin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yi‐Hung Lin. The network helps show where Yi‐Hung Lin may publish in the future.
Co-authorship network of co-authors of Yi‐Hung Lin
This figure shows the co-authorship network connecting the top 25 collaborators of Yi‐Hung Lin. A scholar is included among the top collaborators of Yi‐Hung Lin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yi‐Hung Lin. Yi‐Hung Lin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Jang, Tyng‐Yuan, Yuting Zeng, Po‐Cheng Liang, et al.. (2025). Air Pollution Associated With Mortality Among Chronic Hepatitis B Patients Treated With Nucleotide/Nucleoside Analogues. Alimentary Pharmacology & Therapeutics. 61(9). 1458–1466.
2.
Jang, Tyng‐Yuan, Chih‐Wen Wang, Po‐Cheng Liang, et al.. (2025). Steatotic Liver Disease‐Related Polygenetic Risk Score Prediction of Hepatocellular Carcinoma in Nucleotide/Nucleoside Analog‐Treated Chronic Hepatitis B. Journal of Gastroenterology and Hepatology. 40(9). 2290–2299.
3.
Huang, Chung‐Feng, Chih‐Wen Wang, Tyng‐Yuan Jang, et al.. (2024). Surveillance Imaging and GAAD/GALAD Scores for Detection of Hepatocellular Carcinoma in Patients with Chronic Hepatitis. Journal of Clinical and Translational Hepatology. 0(0). 0–0.
4.
Huang, Chung‐Feng, Po‐Cheng Liang, Chih‐Wen Wang, et al.. (2024). Performance of noninvasive seromarkers in predicting liver fibrosis among MAFLD patients with or without viral hepatitis. The Kaohsiung Journal of Medical Sciences. 40(4). 374–383.
5.
Lin, Yi‐Hung, Meng‐Hung Lin, Chung‐Sheng Shi, et al.. (2024). The impact of fetuin-A on predicting aortic arch calcification: secondary analysis of a community-based survey. Frontiers in Cardiovascular Medicine. 11.
6.
Jang, Tyng‐Yuan, Po‐Cheng Liang, Yu‐Ju Wei, et al.. (2023). Air pollution associate with advanced hepatic fibrosis among patients with chronic liver disease. The Kaohsiung Journal of Medical Sciences. 40(3). 304–314.
7.
Huang, Jee‐Fu, Pei‐Chien Tsai, Ming‐Lun Yeh, et al.. (2023). Community-centered Disease Severity Assessment of Metabolic Dysfunction-associated Fatty Liver Disease. Journal of Clinical and Translational Hepatology. 0(0). 0–0.
8.
Liang, Po‐Cheng, Pei‐Chien Tsai, Po‐Yao Hsu, et al.. (2023). A people-centered decentralized outreach model toward HCV micro-elimination in hyperendemic areas: COMPACT study in SARS Co–V2 pandemic. Journal of Microbiology Immunology and Infection. 56(3). 586–597.
9.
Huang, Chung‐Feng, Po‐Cheng Liang, Pei‐Chien Tsai, et al.. (2023). The interplay of metabolic dysfunction‐associated fatty liver disease and viral hepatitis on liver disease severity: A large community‐based study in a viral endemic area. Journal of Gastroenterology and Hepatology. 39(1). 193–201.
10.
Hsu, Po‐Yao, Po‐Cheng Liang, Ching‐I Huang, et al.. (2022). Effects of Achieving SVR on Clinical Characteristics and Surgical Outcomes in Patients Who Developed Early-Stage HCV-Related Hepatocellular Carcinoma and Received Curative Resection: Preoperative versus Postoperative SVR. Viruses. 14(11). 2412–2412.
11.
Tsai, Yi‐Shan, Ching‐I Huang, Pei‐Chien Tsai, et al.. (2022). Circulating Let-7 Family Members as Non-Invasive Biomarkers for Predicting Hepatocellular Carcinoma Risk after Antiviral Treatment among Chronic Hepatitis C Patients. Cancers. 14(8). 2023–2023.
12.
Tsai, Pei‐Chien, Chia‐Yen Dai, Ching‐I Huang, et al.. (2022). Low disease awareness as a contributing factor to the high prevalence of hepatitis C infection in Tzukuan, a hyperendemic area of southern Taiwan. The Kaohsiung Journal of Medical Sciences. 38(7). 694–702.
13.
Jang, Tyng‐Yuan, Yi‐Hung Lin, Po‐Cheng Liang, et al.. (2022). Amelioration of glucose intolerance through directly acting antiviral agents in chronic hepatitis C cirrhotic patients without overt diabetes. The Kaohsiung Journal of Medical Sciences. 38(9). 897–906.
14.
Huang, Ching‐I, Ming‐Lun Yeh, Chung‐Feng Huang, et al.. (2022). Persistent cryoglobulinemia after antiviral treatment is associated with advanced fibrosis in chronic hepatitis C patients. PLoS ONE. 17(5). e0268180–e0268180.
15.
Yeh, Ming‐Lun, Po‐Cheng Liang, Ching‐I Huang, et al.. (2021). Seroreversion of hepatitis B surface antigen among subjects with resolved hepatitis B virus infection: A community‐based cohort study. Journal of Gastroenterology and Hepatology. 36(11). 3239–3246.
16.
Jang, Tyng‐Yuan, Chung‐Feng Huang, Ming‐Lun Yeh, et al.. (2021). Serum Wisteria floribunda agglutinin‐positive Mac‐2‐binding protein expression predicts disease severity in nonalcoholic steatohepatitis patients. The Kaohsiung Journal of Medical Sciences. 38(3). 261–267.
17.
Tsai, Yi‐Shan, Ming‐Lun Yeh, Pei‐Chien Tsai, et al.. (2020). Clusters of Circulating let-7 Family Tumor Suppressors Are Associated with Clinical Characteristics of Chronic Hepatitis C. International Journal of Molecular Sciences. 21(14). 4945–4945.
18.
Huang, Chung‐Feng, Ming‐Lun Yeh, Ching‐I Huang, et al.. (2019). Ribavirin facilitates early viral kinetics in chronic hepatitis C patients receiving daclatasvir/asunaprevir. Journal of Gastroenterology and Hepatology. 35(1). 151–156.
19.
Jang, Tyng‐Yuan, Ching‐I Huang, Ming‐Lun Yeh, et al.. (2019). Improvement of hyperuricemia in chronic hepatitis C patients receiving directly acting antiviral agents. Journal of Gastroenterology and Hepatology. 35(3). 473–481.
20.
Tsai, Pei‐Chien, Ta‐Wei Liu, Meng‐Hsuan Hsieh, et al.. (2016). A real‐world impact of cost‐effectiveness of pegylated interferon/ribavarin regimens on treatment‐naïve chronic hepatitis C patients in Taiwan. The Kaohsiung Journal of Medical Sciences. 33(1). 44–49.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Alica Kubesch Breakdown of academic impact, for papers by I Nakajima Breakdown of academic impact, for papers by Yoo Sang Yoon Breakdown of academic impact, for papers by Gabriel Ionescu Breakdown of academic impact, for papers by Russell Wesson Breakdown of academic impact, for papers by Hellevi Ruokonen Breakdown of academic impact, for papers by Charles Morrison Breakdown of academic impact, for papers by M. de la Torre Breakdown of academic impact, for papers by Antonio Ramos‐De la Medina Breakdown of academic impact, for papers by Rebecca J. Cannan